Integrity in Science
Return to CSPI U.S.
Plenary Panel
Integrity in Science
Articles, Press Releases, Reports
Keynote Address
—Brian Baird D-WA
Plenary Debate
—"The Data Quality Act and OMB Peer Review Honest Evaluations or New Tools for Manufacturing Doubt and Delay?"
Panel A
—"Misusing Science To Manufacture Doubt and Delay"
Panel B
—"Corporate and Government Suppression of Research"
Rachel Carson Award
—Presentation of Award to Theo Colborn
After Lunch Speaker
—"Industry-Driven Science and the Corruption of Evidence-Based Medicine"
Plenary Panel
—"Science v. Commerce in Medicine"
Panel A
—"Science Journals, Science Journalism and Disclosure"
Panel B
—"The Real Junk Science"
Final Plenary
—"A Program for Reform"

Science vs. Commerce in Medicine
Pharmaceutical companies and patients stand to gain when a life-saving new medication goes to market, but the financial interests of the drug industry are not always aligned with those of consumers who seek safe and effective products. Panelists discuss instances of industry manipulation of clinical trial results and corporate attacks on scientists as well as incentives for industry to act without bias or malice when examining study conclusions.

Moderator: Alicia Mundy, Senior Fellow, New America Foundation
Audio Introduction [ mp3 - 2,616kb ]


Ralph A. Horwitz
Case Western Reserve University

Bio with Disclosure
Listen to Audio [ mp3 - 5,905kb ]

"Currently the Yale hemorrhagic stroke project remains unchallenged in the scientific literature, although we have become the targets of unceasing attack around litigation and other activities...We remain undaunted in support of our findings."

"We look at our [medical] journals and we see this: [Randomized Controlled Trials] on the one side [and advertisements] on [the other]. And you think, that's the problem, [the advertisements]...Actually, the problem is on [the other side]. It's the fact that [trials] have now become the principle marketing tool of the pharmaceutical companies."

David Healy
Dept. of Psychosocial Medicine
University of Wales

Bio with Disclosure
Listen to Audio [ mp3 - 5,152kb ]

Bruce M. Psaty, M.D., Ph.D.
University of Washington
Medical School

Bio with Disclosure
Listen to Audio [ mp3 - 5,055kb ]

"If I were a neutral observer I would have to characterize the efforts of industry to suppress good science as brilliantly creative."

"Pharmaceutical companies have a critical interest in ensuring that the data they collect to support product licensures is of the highest quality. Concerns about questionable authenticity of a clinical study or even a single patient's record can lead to data being disqualified and placing approval for a drug in jeopardy."

Alan Goldhammer
Associate Vice President for Regulatory Affairs
Pharmaceutical Research and Manufacturers Assc.

Bio with Disclosure
Listen to Audio [ mp3 - 3,601kb ]